Welcome to our dedicated page for Bruker news (Ticker: BRKR), a resource for investors and traders seeking the latest updates and insights on Bruker stock.
Bruker Corporation (BRKR) delivers innovative analytical instrumentation and diagnostic solutions for life sciences, pharmaceuticals, and industrial applications. This news hub provides investors and industry professionals with timely updates on corporate developments, financial performance, and technological advancements.
Access comprehensive coverage of Bruker's press releases, including earnings reports, product launches, strategic partnerships, and regulatory milestones. Our curated news collection simplifies tracking market-moving events and understanding their impact on Bruker's position in scientific instrumentation markets.
Key content categories feature updates across Bruker's business segments - from BSI BioSpin's research tools to BEST's energy innovations. Stay informed about operational expansions, R&D breakthroughs, and quality assurance initiatives that drive the company's global success.
Bookmark this page for direct access to verified Bruker announcements and analysis. Monitor evolving trends in analytical technology through reliable updates from one of the industry's most established instrumentation providers.
Bruker has announced the successful development and testing of the world's first high-resolution 1.3 GHz NMR spectrometer with a stable, standard-bore 54 mm superconducting magnet. The groundbreaking system features a 30.5 Tesla field strength and incorporates a novel ReBCO high-temperature superconductor insert.
The new spectrometer maintains similar physical dimensions and cryogen consumption as Bruker's 1.2 GHz magnets. Testing was conducted using five different NMR probe configurations, demonstrating increased resolution and sensitivity for both liquids and solids NMR spectra.
The technology particularly benefits spectroscopy of bio-macromolecules lacking dispersion, such as carbohydrates, glycoproteins, RNA, and intrinsically disordered proteins. In solid-state applications, the increased field strength improves the study of quadrupolar nuclei by producing narrower spectral lines.
Bruker has unveiled its innovative Fourier 80 multinuclear benchtop FT-NMR spectrometer at the Joint ENC-ISMAR Conference 2025. The new 'Multi-Talent' configuration represents a significant advancement in permanent magnet-based FT-NMR technology.
The system's key features include:
- Capability to measure or decouple 1H and select from 15 different X-nuclei
- Support for X{1H} experiments and 1H{X} experiments
- Enables various 2D experiments and inverse 1H observation methods
- Includes gradient spectroscopy with options for adjustable sample temperature and sample changer automation
- Uses standard 5 mm NMR samples
According to Dr. Agnes Haber, Fourier 80 Product Manager, twelve systems have already been successfully installed in customer labs. The system is particularly valuable for pharmaceutical research and battery development, supporting observations of nuclei like 7Li, 23Na, and 11B for battery electrolyte formulation.
Bruker has announced the successful first customer installation of its revolutionary dissolution Dynamic Nuclear Polarization (d-DNP) Polarizer at the University of California San Francisco (UCSF). The groundbreaking technology enables over 10,000x signal gains on 13C in high-field MRI and NMR systems.
The system operates at 7 Tesla and temperatures below 1.4 Kelvin, featuring Bruker's proprietary active cross-polarization technology that provides 5-10x faster polarization compared to traditional d-DNP of 13C. This advancement is particularly significant for in vivo studies of 13C-labelled metabolites, enabling real-time tracking of metabolic differences between healthy and diseased tissues in conditions like cancer.
The installation at UCSF's Hyperpolarized MRI Technology Resource Center marks a milestone in hyperpolarized MRI for preclinical research, with additional installations planned in Europe and the US. The partnership aims to validate the d-DNP technology in oncology applications.
Bruker (Nasdaq: BRKR) has launched the X4 POSEIDON™, a high-performance benchtop 3D X-ray microscope (XRM) utilizing micro-Computed Tomography technology. The system features a high-end X-ray source that delivers over 10x improvement in 3D resolution compared to similar instruments.
Key features include:
- Large field-of-view high-efficiency detector with optional high-resolution scientific CMOS detector
- 3DxSUITE software with automated protocols and multi-language support
- Low maintenance design for enhanced uptime and reduced ownership costs
- Field-upgradable options for future expansion
The X4 POSEIDON targets applications in geosciences, pharmaceutical R&D, QA/QC, composite materials, batteries, renewable energy, microelectronics, and life sciences including bone, dental, soft tissue, and biological research.
Bruker (Nasdaq: BRKR) announced major advancements in proteomics technology and software at the 21st Annual US HUPO Conference. The company previewed the timsTOF Ultra 2 system with new Athena Ion Processor (AIP), showing 15-20% improvement in protein identification and 20-25% increase in peptide identifications for single-cell proteomics.
Key announcements include:
- Launch of DeutEx™ software for hydrogen-deuterium exchange analysis
- OmniScape™ 2025b with 10x increase in de novo sequencing performance
- Enhanced ProteoScape™ V.2025c with improved Spectronaut® and GlycoScape™ capabilities
- TwinScape™ cloud-based AI monitoring solution for proteomics quality control
The new AIP technology, expected to launch at ASMS 2025, enables better ion transfer and shows similar improvements in immunopeptidomics. GlycoScape v.2025c increases glycopeptide identification by 6x-10x, enabling comprehensive glycoform profiling.
Bruker (BRKR) announced major advancements in spatial biology to be unveiled at AGBT 2025, including four key innovations: CosMx Whole Transcriptome Panel (WTX), capable of detecting over 18,000 RNA transcripts at single-cell resolution; expansion of GeoMx protein panel to 1,000-plex capability; launch of PaintScape, a platform for 3D genome visualization; and enhanced CellScape PowerOMX software engine for spatial proteomics.
The WTX assay will begin taking orders in April with summer shipments, while a Mouse version is expected later in 2025. The expanded GeoMx 1K Panel is scheduled for summer release. The company also announced the Sapphire Spatial Program, offering premium services for CosMx SMI users, and extended collaboration with Weill Cornell Medicine on the Spatial Atlas of Human Anatomy (SAHA) initiative to map 30 non-diseased organs.
Bruker (BRKR) has announced that its Board of Directors has approved a quarterly cash dividend of $0.05 per share on the Company's common stock. The dividend will be paid on March 28, 2025 to stockholders of record as of March 17, 2025.
Bruker (BRKR) has announced its senior leadership's participation in four major investor conferences in early 2025. The schedule includes:
- Citi 2025 Unplugged Medtech and Life Sciences Access Day in New York City (February 27, 2:30 PM ET)
- TD Cowen 45th Annual Health Care Conference in Boston (March 5, 11:10 AM ET)
- Barclays 27th Annual Global Healthcare Conference in Miami (March 11, 2:30 PM ET)
- Leerink 2025 Global Healthcare Conference in Miami (March 12, 11:20 AM ET)
All presentations will be accessible via live audio webcasts on Bruker's Investor Relations website. Replay recordings will remain available for at least 30 days after each event in the 'Events & Presentations' section.
Bruker (BRKR) reported Q4 2024 revenues of $979.6 million, up 14.6% year-over-year, with organic revenue growth of 3.9%. The company's Q4 non-GAAP operating margin maintained at 18.1%, with Q4 non-GAAP diluted EPS reaching $0.76, up 8.6% year-over-year.
For full-year 2024, revenues reached $3.37 billion, showing 13.6% growth, with organic revenue up 4.0%. The company's FY 2024 non-GAAP diluted EPS was $2.41, down 6.6% due to strategic acquisitions impact in H1-24.
Looking ahead, Bruker initiated FY 2025 guidance with expected revenue between $3.47-3.54 billion (3-5% growth) and non-GAAP EPS of $2.67-2.72 (11-13% growth). The company completed several strategic acquisitions in 2024, expanding into spatial biology, molecular diagnostics, and lab automation markets.
Bruker (BRKR) has announced its upcoming fourth quarter and fiscal year 2024 financial results release, scheduled for Thursday, February 13, 2025, before market opening. The company will host a conference call and webcast at 8:30 a.m. Eastern Standard Time to discuss results and current business trends.
Investors can access the webcast through Bruker's investor relations website and view an accompanying slide presentation. For telephone access, participants can dial 1-888-437-2685 (U.S. toll-free) or +1-412-317-6702 (international). Pre-registration is available to expedite call entry. A replay will be accessible until March 13, 2025, via 1-877-344-7529 (U.S. toll-free) or +1-412-317-0088 (international) using code 5344184.
FAQ
What is the current stock price of Bruker (BRKR)?
What is the market cap of Bruker (BRKR)?
